Pages that link to "Q37706505"

The following pages link to A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers (Q37706505):

Displaying 11 items.

• Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications (Q26996400) (← links)
• PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity (Q36225827) (← links)
• PX-12-induced HeLa cell death is associated with oxidative stress and GSH depletion (Q37325166) (← links)
• Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling (Q38777221) (← links)
• Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma (Q38878577) (← links)
• PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner (Q38940920) (← links)
• Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers (Q41874296) (← links)
• Redox-Inactive Peptide Disrupting Trx1-Ask1 Interaction for Selective Activation of Stress Signaling (Q47271512) (← links)
• Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories (Q61660008) (← links)
• Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer (Q64235689) (← links)
• The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs (Q91724079) (← links)